Table 2 Licensed indications of different aromatase inhibitors
From: Update on the use of aromatase inhibitors in early-stage breast cancer
Treatment | Newly diagnosed patients | Patients currently treated with tamoxifen |
|---|---|---|
Anastrozole | Primary adjuvant | Unplanned switch following 2 to 3 years of tamoxifen |
Exemestane | Not applicable | Unplanned switch following 2 to 3 years of tamoxifen |
Letrozole | Primary adjuvant | Unplanned switch following 5 years of tamoxifen (extended adjuvant) |